Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Return on Sales (2020 - 2025)

Harmony Biosciences Holdings' Return on Sales history spans 6 years, with the latest figure at 0.09% for Q4 2025.

  • For Q4 2025, Return on Sales fell 24.0% year-over-year to 0.09%; the TTM value through Dec 2025 reached 0.18%, down 4.0%, while the annual FY2025 figure was 0.18%, 4.0% down from the prior year.
  • Return on Sales for Q4 2025 was 0.09% at Harmony Biosciences Holdings, down from 0.21% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.75% in Q3 2022 and bottomed at 0.29% in Q4 2022.
  • The 5-year median for Return on Sales is 0.23% (2022), against an average of 0.2%.
  • The largest annual shift saw Return on Sales surged 207bps in 2021 before it crashed -54bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 0.25% in 2021, then crashed by -218bps to 0.29% in 2022, then skyrocketed by 154bps to 0.16% in 2023, then surged by 109bps to 0.33% in 2024, then tumbled by -72bps to 0.09% in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Return on Sales are 0.09% (Q4 2025), 0.21% (Q3 2025), and 0.2% (Q2 2025).